Clinical Trial Update: Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating tumor-associated antigen-specific cytotoxic T-lymphocytes for multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Tumor-associated antigen-specific cytotoxic T-lymphocytes (TAA-CTLs)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Multiple Myeloma | Phase 1 | Status: RECRUITING